Pharma Equity's subsidiary, Reponex, reports highly positive phase-2 trial results for RNX-051.

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals, reports highly positive final results from the phase-2 clinical trial of their patented drug candidate RNX-051. The trial results are considered a significant milestone for the company.